glp 1 for chronic inflammation GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies The expanding landscape of GLP-1

The kidneys benefit through mechanisms that are largely body-weight-independent, while some cardiovascular benefit in leaner patients may be attenuated

Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al

Hajjar et al., 2018), reduced verbal fluency(Pia et al., 2016), reduced motor control(Hockenberry et al., 2015

Randomised placebo-controlled multicentre trial to evaluate the efficacy and safety of JTR-161, allogeneic human dental pulp stem cells, in patients with acute ischaemic stroke (J-REPAIR)

Additional studies are needed to evaluate safety, efficacy, and proper use of GLP-1 agonists for dermatologic conditions to consider expanding their approval beyond T2DM and weight loss